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Abstract 
Heart failure is a major cause for premature death. Given heterogeneity of the heart failure 
syndrome, identifying genetic determinants of cardiac function and structure may provide greater 
insights into heart failure. Despite progress in understanding the genetic basis of heart failure 
through genome wide association studies, heritability of heart failure is not well understood. 
Gaining further insights into mechanisms that contribute to heart failure requires systematic 
approaches that go beyond single trait analysis.  
We integrated Bayesian multi-trait approach and Bayesian networks for the analysis of 10 
correlated traits of cardiac structure and function measured for 3387 individuals with whole 
exome sequence data. While using single-trait based approaches did not find any significant 
genetic variant, applying the integrative Bayesian multi-trait approach, we identified 3 novel 
variants located in genes, RGS3, CHD3, and MRPL38 with significant impact on the cardiac 
traits such as left ventricular volume index, parasternal long axis interventricular septum 
thickness, and mean left ventricular wall thickness. Among these, the rare variant 
NC_000009.11:g.116346115C>A (rs144636307) in RGS3 showed pleiotropic effect on left 
ventricular mass index, left ventricular volume index and Maximum left atrial anterior-posterior 
diameter while RGS3 can inhibit TGF-beta signaling associated with left ventricle dilation and 
systolic dysfunction.  
Keywords: Bayesian networks, cardiac structure and function, integrative approach, multiple 
traits, pleiotropy, rare variants, RGS3.   
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Introduction 
Heart failure (HF) is a complex clinical syndrome characterized by abnormal cardiac structure 
and function that  leads to reduced cardiac output and elevated filling pressures at rest or with 
exertion (1). Although, there is increasing evidence that the risk and course of HF depend on 
genetic predispositions (2), genome wide association studies (GWAS) have identified only a 
handful of genetic variants associated with it. For instance, the chromosome region 9p21 
includes several highly replicated genetic variants associated with HF risk factors (e.g. 
NC_000009.11:g.22096055A>G and NC_000009.11:g.22124477A>G) (3).  The effect allele G 
of the first variant is intronic to gene CDKN2B-AS1 while the same effect allele in the second 
variant is located in an enhancer and disrupts a binding site for STAT1 (4).  
For better understanding heritability of HF, some studies combine results of multiple cohort and 
involve more samples in the analysis through meta-analysis (5). One of the largest studies of 
these on African-American population identified four variants including 
NC_000008.10:g.49171227A>G (rs4552931) and NC_000017.10:g.66685847C>T (rs7213314) 
associated with left ventricular mass and left ventricular internal diastolic diameter respectively 
using Echocardiography (6). A meta-analysis on 5 cohorts of individuals with European ancestry 
identified five genetic loci harboring common variants associated with left ventricular diastolic 
dimensions and aortic root size (7). More recently, a meta-analysis through studying a large set 
of samples including 73,518 individuals identified 32 novel loci associated with 
electrocardiographic markers of hypertrophy as an important and independent risk factor for the 
development of heart failure (8). 
Taking advantage of dozens-to-hundreds of traits measured on each study participant creates 
opportunities to obtain insights into systems biology of HF, and consequently reduces morbidity, 
and economic burden of HF. Multi-trait analysis is toward this aim and increases the statistical 
power (9)(10)(11)(12). Although there are many studies on multi-trait approaches, applications 
of those methods have recently received increased attention e.g.  (13)(14)(15). A limitation of 
those methods is their complexity due to the large number of parameters in the model.  
To reduce the complexity of the multi-trait models due to the number of parameters, we here 
integrated Bayesian network (16)  with a Bayesian polygenic mixed model while setting G-
Wishart prior on covariance matrix (17) and called it Integrative Bayesian Multi-Trait (IBMT) 
approach. Using IBMT approach, we conducted an analysis to identify genomic variants 
influencing 10 echocardiographic traits related to cardiac structure and function from 
Atherosclerosis Risk in Communities (ARIC) study (18). We have genotype data of 7810 
European American individuals from baseline measurement while 3387 of these individuals have 
phenotype records in Visit 5. The phenotype data are also recorded for 1265 new participants at 
visit 5 who do not have baseline genotype. Thus, we had three sets of data, including i) 
individuals with only genotype data, ii) individuals with only phenotype data, and iii) individuals 
with both genotype and phenotype data. We incorporated information from all these three sets 
3 
 
into the analysis to improve the statistical power, prevent overfitting, and avoid using data 
multiple times. The details are provided in the Methods section. These steps ultimately improve 
reliability and generalizability of the results.  
After data preparation, we applied the IBMT method over the whole exome sequence data to 
investigate genomic and cardiac trait relationships. We identified 3 genetic variants 
(NC_000009.11:g.116346115C>A, NC_000017.10:g.7802658C>T, NC_000017.10: g.73897977 
C>T) in genes RGS3, CHD3, and MRPL38 with significant impact on the cardiac traits such as 
left ventricular volume index, parasternal long axis interventricular septum thickness, and mean 
left ventricular wall thickness. Gene RGS3 codes for GTPase-activating protein that inhibits G-
protein-mediated signal transduction. CHD3 encodes a protein with a chromatin organization 
modifier domain and a SNF2-related helicase/ATPase domain. MRPL38 produces a 
mitochondrial ribosomal protein, involved in the synthesis of proteins within the mitochondrion. 
The variant in RGS3 gene (NC_000009.11:g.116346115C>A) showed pleiotropic gene action on 
vertical mass index, left ventricular volume index and Maximum left atrial anterior-posterior 
diameter) while RGS3 can inhibit TGF-beta signaling associated with left ventricle dilation and 
systolic dysfunction.  
Materials and Methods 
Study population 
Echocardiographic and genomic data were collected on a subset of the ARIC study, a biracial 
longitudinal cohort of 15,792 middle-aged individuals who were randomly sampled from four 
US sites (Forsyth County, NC; Jackson, MS; suburbs of Minneapolis, MN; and Washington 
County, MD) and have been measured for risk factor traits related to health and chronic diseases. 
A detailed description of the ARIC study design and methods have been published elsewhere 
(18)(19). The data presented here includes 7810 European American individuals with baseline 
genotype available on dbGAP (https://www.ncbi.nlm.nih.gov/gap), accession number 
phs000090.v1.p1. A subset of individuals with genotype data, 3387 out of 7810 individuals, has 
phenotype records at visit 5. The phenotype data described in the following subsection are also 
recorded for 1265 new participants at visit 5 who do not have baseline genotype. Figure 1 
visualized study population with phenotype and genotype records through Venn diagram.  
 
Figure 1. Venn diagram of study population with phenotype and genotype records. 
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Echocardiographic methods and measurements 
Echocardiograms were obtained from participants at visit 5 using a standardized protocol as 
recommended by the American Society of Echocardiography. Images were digitally transferred 
to the Cardiovascular Imaging Core Laboratory at Brigham and Women’s Hospital, Boston, MA, 
for offline analysis. The intra-observer variability (coefficient of variation and interclass 
correlation) for key echocardiographic measures has been previously published (20). Images 
were obtained in the parasternal long- and short-axis and apical 2- and 4-chamber views. Primary 
measures of the traits such as left ventricular (LV) dimensions, volumes, and wall thickness; left 
atrial (LA) dimension, volume, and area were made in triplicate from the 2-dimensional views in 
accordance with the recommendations of the American Society of Echocardiography (21). This 
study includes 10 cardiac structure and function tabulated in Table 1. LV mass was calculated 
from LV linear dimension and indexed to body surface area. Relative wall thickness was 
calculated using the posterior wall thickness and LV end-diastolic dimension. LA volumes were 
measured by methods of disks using apical 4- and 3- chamber views. LV volumes were 
calculated from the apical 4- and 2- chamber views utilized the modified Simpson method.  
Table 1. Cardiac structural and functional traits under study. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Whole exome sequencing 
Whole exome sequencing was performed on samples with the Illumina HiSeq platform. Mercury 
pipeline is applied for variant calling (22). The reads are mapped into the Genome Reference 
Consortium Human Build 37 (GRCh37) sequence. Low-quality variants are filtered if they were 
outside the exon capture regions, belonged to multi-allelic sites, had missing rate > 20% and had 
Phenotypes of Interest 
Name Measurement 
Parasternal long axis interventricular septum thickness (PLAx-IST) 
Parasternal long axis posterior wall thickness (PLAx-PWT) 
End-diastolic volume (ED-V) 
End-systolic volume (ES-V) 
Ejection fraction (EF) 
LV mass index (LV-MI) 
LV relative wall thickness (LV-RWT) 
Mean LV wall thickness (LV-WT) 
Maximal left atrial anterior-posterior diameter (Max-LA-APD) 
LA volume index (LA-VI) 
Cm 
Cm 
Ml 
Ml 
% 
G per m2 
 
Cm 
Cm  
Ml per m2 
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mean depth of coverage > 500-fold. In addition, highly significant departures from race-specific 
Hardy-Weinberg equilibrium (P-value < 5e-6) are excluded from the data. 
Statistical methods 
Adjusting covariates 
There is a broad consensus on analytic techniques for covariate adjustment to discover genomic 
variants associated with traits of interest independently of the correlated covariates and improve 
statistical power by gaining precision. The set of covariates typically include principal 
components of individual genotypes to account for population structure, correlated 
environmental or demographic factors such as gender and age.  However, some of those 
covariates may not have significant impact on the traits and the adjustment may contaminate the 
data. Therefore, instead of adjusting each trait for all routine covariates, we first investigated the 
effect of covariates on the traits using 1265 individuals with only phenotypic record. This not 
only prevents decreasing the statistical precision or contaminating data due to adjusting for 
unrelated covariates but also avoids using data twice which prevents overfitting.   
Applying an Integrative Bayesian Multi-Trait approach 
We applied Empirical Bayesian approach for analysis of multiple correlated traits. We first 
identified underlying relationships of the 10 cardiac functional and structural traits tabulated in 
Table 1 via application of Bayesian networks. The analysis was carried out at a statistical 
significance level of 0.05 determined by structural Hamming distance (23)(24)(25). The 
identified network, which is also supported by clinical background knowledge, revealed the 
sparsity level of the relationships. Figure 2 displays the network, where the nodes are the traits 
and the edges represent a significant relationship between the two corresponding traits after 
excluding the effect of the other traits. Clustering approaches (26)(27) can be also applied for the 
same purpose, although they may estimate more connections among the traits. The Bayesian 
network was built on the subset of individuals with only phenotype records to avoid overfitting.  
 
Figure 2. The Bayesian Network over the cardiac traits. The colors correspond to the degree of 
connectivity of each trait; deeper color means greater connectivity. 
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We integrated the identified underlying relationships among the traits with a Bayesian polygenic 
mixed model while setting G-Wishart prior on covariance matrix and called it Integrative 
Bayesian Multi-Trait (IBMT) approach. Applying the IBMT, we optimized performance and 
computational time of Gibbs Sampling Scheme due to the decrease on the number of parameters 
of the model. Further details of the model and Gibbs sampling scheme are provided in the 
Supplementary statistical methods section.  
Using the identified Bayesian network over the traits, we implemented the IBMT method and 
analyzed the whole exome sequencing data including 260,688 variants based on sliding window. 
Each window included 100 variants with a step size of 25, such that each variant appears in 4 
windows. If a variant is selected in all 4 windows, we reported the variant as the most promising 
variants. The parameters of the model were updated at each iteration of Markov Chain Monte 
Carlo (MCMC) algorithm and estimated with posterior means, which calculate optimal point 
estimators under square error loss, after 200 burn-in period. 
To identify genomic variants significantly associated with the traits, we calculated 98% credible 
interval (28)(29), ( 𝑞 L, 𝑞U), for the effects of all the variants to test a null hypothesis of no 
genomic effects. The endpoints of the intervals correspond to quantile (q) of the empirical 
distribution of the MCMC drown from the marginal posterior distribution of genetic effects. A 
desired degree of precision for the endpoints of intervals is achieved by running a number of 
iterations until  
𝑃(|𝑞𝑖
𝐿 −   𝑞𝑖−1
𝐿 |) <  𝜁,         𝑃(|𝑞𝑖
𝑈 −   𝑞𝑖−1
𝑈 |) <  𝜁, 
where  𝑞 L and  𝑞U are lower and upper quantile respectively and i represents the number of 
iterations. We set ζ to 0.01 as a small value.  
Results 
Since the IBMT method is based on a linear polygenic mixed model, we first tested the 
normality of the traits as a fundamental assumption. Except ejection fraction and maximal left 
atrial anterior-posterior diameter that are normally distributed, the other traits have been 
transformed to normal using log transformation. The histograms of the traits after winsorization, 
standardization, and log transformation are represented in Supplementary Figure1. 
We then investigated the effects of gender, age, ever-smoked, body mass index (BMI), 
hypertension, systolic and diastolic blood pressure on the traits. Among them gender and BMI 
showed highly significant relationships (P-value < 1e-8) with all traits except mean LV Wall 
Thickness (LV-WT) and ejection fraction, which they were relatively less significant with, P-
values 0.05 and 0.005 respectively. Hypertension also showed significant effects (P-value < 1e-
6) with all traits except ejection fraction. We obtained these results on the set of individuals 
without genotype data to avoid the use of data twice. To generalize the results to the set of 
interest (individuals with both genotype and phenotype records), we compared BMI distribution, 
gender ratio (Female/Male), and ratio of (with/without) hypertension in the two sets. We 
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observed that in both sets, the distribution of BMI is similar (Figure 3); gender ratios 1.302 and 
1.387 showed almost the same proportion of female to male; and hypertension ratios 2.502 and 
2.579 also showed almost the same proportion of individuals with and without hypertension. 
Therefore, we adjusted the traits for BMI, gender, and hypertension, in addition to the first 10 
PCs from population stratification analysis. 
 
 
Figure 3. Histogram of BMI. Right: individuals without genotype data.  Left: individuals with 
genotype data. 
Applying IBTM, we first identified Bayesian network among 10 traits listed in Table 1. As 
shown in Figure 2, underlying relationships among the traits are sparse. Therefore, we do not 
need to consider all pairwise connectivity in the analysis. Incorporating this result into multi-trait 
mixed model, we reduced the number of parameters in the model and consequently increased the 
power of genotype-phenotype identification (Supplementary Statistical methods). We could 
identify 3 genetic variants with significant impact on 4 cardiac traits using a 98% credible 
interval (Table 2 and Figure 4). Minor allele frequencies (MAF) in Table 2 show the identified 
variants are rare. Table 3 reports the estimated effects of the identified variants.  
 
 
Figure 4: Identified genetic pathway to cardiac structure and function using IBMT. 
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Table 2. Selected genomic variants related to the traits, using a 98% Bayesian credible 
interval. HGVS name is description of sequence variation in genomic established by The 
Human Genome Variation Society; refSNP ID is a unique identifier provided by NCBI; 
CHR is the chromosome number; and MAF stands for minor allele frequency. 
 
 
Figure 5 shows empirical distributions of LV-MI (red/blue) for individuals with 
reference/alternative allele of one of the identified variants (NC_000017.10:g.73897977C>T). 
The noticeable shift of the distribution for individuals with mutation is observable. 
Supplementary Figure 2 shows levels of the traits for individuals with identified rare mutation 
over distribution of the traits.  
 
 
Figure 5. Empirical Distributions of log(LV-MI) for individuals with reference/alternate alleles 
for NC_000017.10:g.73897977C>T variant. 
Identified variants 
HGVS name refSNP ID CHR MAF% Gene name Related trait 
NC_000009.11:g.116346115C>A  
 
 
NC_000017.10:g.7802658C>T   
 
NC_000017.10:g.73897977C>T 
rs144636307 
 
 
rs200287864 
 
rs76054219 
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17 
 
17 
0.38 
 
 
0.25 
 
0.32 
RGS3 
 
 
CHD3 
 
MRPL38 
LV-MI  
LA-VI 
Max-LA-APD       
 PLAx-IST 
 
LV-MI 
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Table 3. Estimated effect (Est-Eff) and standard deviation (SD-Eff) of the 
identified genes with significant effect on the traits. 
 
 
 
  
 
 
 
 
 
 
 
One of the identified variants located in chromosome 9 (NC_000009.11:g.116346115C>A) 
showed pleotropic effect on LV-MI, LA-VI and Max-LA-APD. Among 14 individuals (5 
Females and 9 Males) having rare mutation in RGS3 (NC_000009.11:g.116346115C>A) with 
pleiotropic action, two of the females and one male showed different patterns with other 
individuals, such that their level of LV-MI, LA-VI and Max-LA-APD are not greater than third 
quartiles (Supplementary Figure 2). This suggests that the rare mutation identified in RGS3 may 
have higher impact on males. In addition, pleiotropic effect of this variant may represent 
different functions of the RGS3 gene. 
According to the Variant Effect Predictor (VEP) analysis (30), this variant is most likely a 
missense mutation in RGS3 (regulator of G protein signaling 3) gene. It yields a codon change 
from ACC to AAC replacing the amino acid Threonine (Thr) by an Asparagine (Asn) in the 
protein sequence. RGS genes encode proteins that act as GTPase activating proteins (GAPs) and 
down-regulate G protein signaling. More details about the results from the VEP analysis is 
provided in Supplementary Table 1. 
Another identified variant with impact on PLAx-IST is in chromosome 17 
(NC_000017.10:g.7802658C>T). Individuals with T allele of this rare variant, including 2 
Females and 8 Males, all have PLAx-IST level greater than third quartile of the trait 
(Supplementary Figure 2). 
The variant NC_000017.10:g.7802658C>T is intronic to Chromatin Helicase DNA Binding 
Protein 3 (CHD3) gene based on VEP analysis (Supplementary Table 2). CHD3 belongs to a 
family of genes coding for proteins that bear CHROMO (chromatin organization modifier) and 
SNF2-related helicase/ATPase domains. CHD3 protein is one of the components of the Mi-
HGVS name Trait Est-Eff SD-Eff 
NC_000009.11:g.116346115C>A 
NC_000009.11:g.116346115C>A 
NC_000009.11:g.116346115C>A 
NC_000017.10:g.7802658C>T 
NC_000017.10:g.73897977C>T 
LV-MI 
LA-VI 
Max-LA-APD 
PLAx-IST 
LV-MI 
1.13 
1.27 
1.29 
1.48 
1.28 
0.104 
0.110 
0.102 
0.186 
0.153 
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2/NuRD (histone deacetylase) complex that participates in the remodeling of chromatin structure 
via histone deacetylation.  
The third identified genetic variant influencing LV-MI is located in chromosome 17, gene 
MRPL38 (NC_000017.10:g.73897977C>T). All 8 male individuals with rare mutation in 
MRPL38 have LV-MI level greater than third quartiles of distribution (Supplementary Figure 2). 
However, the 2 female individuals do not show any different pattern.  
The variant NC_000017.10:g.73897977C>T can be in a non-coding exon or be a missense 
mutation of MRPL38 gene. The missense mutation of CGG into CAG codon causes the 
substitution of amino acid Arginine (Arg) by a Glutamine (Gln) concluded. Gln is a non-charged 
amino acid and smaller than Arg with putatively less capacity to create hydrogen bonds and 
favorable electrostatic interactions than Arg (see Supplementary Table 3 for VEP results). 
MRPL38 encodes mitochondrial ribosomal proteins (MRP). Family MRPs stabilize 
mitochondrial ribosome (mitoribosome) and are responsible for the mitochondrial translation of 
13 protein components of the Oxidative Phosphorylation (OXPHOS) gene complex in the 
mitochondrial DNA (31).  
Discussion  
Single trait analysis did not identify any genetic variants with significant impact on the 10 
considered traits of cardiac structure and function in European American individuals from ARIC 
study. Therefore, we integrated Bayesian network and Bayesian multi-trait approach to improve 
the performance of the analysis. This Integrative Bayesian Multi-Trait (IBMT) approach 
provides sparse precision matrix and, eventually, more precise estimates of parameters in the 
model. Utilizing the IBMT method to increase the power of identification, in addition to 
carefully adjusting for covariates to avoid data contamination, and choosing the appropriate 
transformation function for each trait, we identified three significant genetic variants. These 
variants located in RGS3, CHD3, and MRLP38 genes are rare  which requires a high statistical 
power to detect any association with trait(s) (32)(33)(34)(35). Among those, the variant 
NC_000009.11:g.116346115C>A in RGS3 showed pleiotropic action on vertical mass index, left 
vertical volume index, Maximum left atrial anterior-posterior diameter (Figure 4).  
The variant NC_000009.11:g.116346115C>A is in the exon of gene RGS3 (Regulator of G 
protein signaling 3) which belongs to RGS family. RGS family codes for proteins that act as 
GAPs and down-regulate G protein signaling. Many studies have proven that RGS gene 
expression is highly regulated in myocardium (36)(37)(38). Quantitative messenger RNA 
(mRNA) analysis revealed that RGS3 is most highly expressed in human heart (39)(40)(41). The 
N-terminus of RGS3 can inhibit TGFβ induced differentiation of pulmonary fibroblasts which is 
associated with left ventricular dilation and systolic dysfunction (42)(43)(44). The identified 
variant in RGS3 was associated with pleotropic effect on LV mass (LV-MI) and measures of left 
atrial size (LA-VI and Max-LA-APD). The left atrial size may reflect the cumulative effects of 
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increased LV filling pressure and diastolic function (45) and is a predictor of heart failure, 
ischemic stroke, and death. Thus, genetic variants contributing to abnormalities of LV mass and 
worsened diastolic function would be expected to potentially be associated with LA size.  
As missense mutation, NC_000009.11:g.116346115C>A yields a codon change from ACC to 
AAC, which replaces a Threonine (Thr) to an Asparagine (Asn) in the protein amino acid 
sequence. The change from Thr to Asn does not alter side chain electrostatic charge because of 
both amino acids being electrostatically neutral. This could eventually affect hydrogen bond 
pattern since Asn has an extra hydrogen bond donor group (NH2). However, it is difficult to 
evaluate the final effect in the protein three dimensional structure since there may be alternative 
spliced transcripts. If this mutation happened at the interaction interface between RGS3 and G 
subunit, it could eventually affect GTPase activity.  
The variant NC_000017.10:g.7802658C>T that is significantly associated with parasternal long 
axis interventricular septum thickness (PLAx-IST) is in an intron of the CHD3 gene, which 
codes for the Chromatin Helicase DNA Binding Protein 3 as a part of the chromatin structure 
remodeling complex. This variant is a potential splicing variant that could affect the rate of 
mature mRNA synthesis, and ultimately impact gene transcription.  
The other identified variant NC_000017.10:g.73897977C>T is within MRPL38 gene, a member 
of Mitochondrial ribosomal proteins (MRP) family that are part of the large subunit of the 
mitochondrial ribosome. As missense mutation, the change of CGG into CAG codon causes the 
substitution of amino acid Arginine (Arg) by a Glutamine (Gln). Gln is a non-charged amino 
acid and smaller than Arg with putatively less capacity to create hydrogen bonds and favorable 
electrostatic interactions than Arg. If the amino acid mutation takes place at the interface 
between MRPL38 and mitochondrial ribosome, it could decrease binding affinity and destabilize 
mitochondrial ribosome. This in turn may reduce ribosomal protein synthesis levels and affect 
the oxidative phosphorylation pathway. 
Overall, this study suggests that rare mutation might provide a better understanding of genetic 
impact on cardiovascular structure and resulting in remodeling cardiovascular disease and/or 
heart failure, although the analysis requires new approaches.  
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Supplementary Figures 
 
Supplementary Figure 1 
The histogram of the traits in Table1 after winsorization, standardization, and normal transformation  
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Supplementary Figure 2 
Empirical Distributions of the traits in Table 3 for individuals with Reference allele: The yellow vertical 
line shows the third quartiles of the distribution. Individuals with alternative allele are represented with 
blue vertical line.  
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Supplementary Tables 
The VEP analysis results for identified genetic variants are summarized in the following tables where  
 HGVS name: description of sequence variation in genomic established by the Human Genome Variation 
Society  
 Consequence: consequence type of the allele on transcript  
 AA_AF/EA_AF: African Americans/ European Americans allele frequency in NHLBI-ESP data base 
 HGVSp: HGVS protein sequence name 
Supplementary Table 1 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
HGVS name Allele Consequence Gene 
symbol 
Biotype Exon Intron HGVSp Amino 
acids 
Codons 
NC_000009.11: 
g.116346115C>A 
A missense_variant RGS3 protein_ 
coding 
2/7 - NP_001263189.1: 
p.Thr129Asn 
T/N aCc/aAc 
NC_000009.11: 
g.116346115C>A 
A intron_variant RGS3 protein_ 
coding 
- 10/14 - - - 
NC_000009.11: 
g.116346115C>A 
A missense_variant RGS3 protein_ 
coding 
3/8 - NP_001269851.1: 
p.Thr129Asn 
T/N aCc/aAc 
NC_000009.11:g. 
116346115C>A 
A missense_variant RGS3 protein_ 
coding 
18/23 - NP_001269852.1: 
p.Thr698Asn 
T/N aCc/aAc 
NC_000009.11: 
g.116346115C>A 
A missense_variant RGS3 protein_ 
coding 
2/7 - NP_001309144.1: 
p.Thr147Asn 
T/N aCc/aAc 
NC_000009.11: 
g.116346115C>A 
A missense_variant RGS3 protein_ 
coding 
11/16 - NP_570613.2: 
p.Thr527Asn 
T/N aCc/aAc 
NC_000009.11: 
g.116346115C>A 
A intron_variant RGS3 protein_ 
coding 
- 1/4 - - - 
NC_000009.11: 
g.116346115C>A 
A missense_variant RGS3 protein_ 
coding 
21/26 - NP_652759.3: 
p.Thr808Asn 
T/N aCc/aAc 
NC_000009.11: 
g.116346115C>A 
A non_coding_ 
transcript_ 
exon_variant 
RGS3 misc_RNA 18/23 - - - - 
NC_000009.11: 
g.116346115C>A 
A non_coding_ 
transcript_ 
exon_variant 
RGS3 misc_RNA 3/8 - - - - 
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Supplementary Table 2 
 
 
 
 
 
 
 
Supplementary Table 3 
HGVS name Allele Consequence Gene 
symbol 
Biotype Exon Intron HGVSp Amino 
acids 
Codons 
NC_000017.10: 
g.7802658C>T 
T splice_region_ 
variant,intron_ 
variant 
CHD3 protein_ 
coding 
- 14/39 - - - 
NC_000017.10: 
g.7802658C>T 
T splice_region_ 
variant,intron_ 
variant 
CHD3 protein_ 
coding 
- 14/39 - - - 
NC_000017.10: 
g.7802658C>T 
T splice_region_ 
variant,intron_ 
variant 
CHD3 protein_ 
coding 
- 14/38 - - - 
NC_000017.10: 
g.7802658C>T 
T splice_region_ 
variant,intron_ 
variant 
CHD3 protein_ 
coding 
- 14/39 - - - 
NC_000017.10: 
g.7802658C>T 
T splice_region_ 
variant,intron_ 
variant 
CHD3 protein_ 
coding 
- 14/38 - - - 
NC_000017.10: 
g.7802658C>T 
T splice_region_ 
variant,intron_ 
variant 
CHD3 protein_ 
coding 
- 14/39 - - - 
NC_000017.10: 
g.7802658C>T 
T splice_region_ 
variant,intron_ 
variant 
CHD3 protein_ 
coding 
- 14/33 - - - 
NC_000017.10: 
g.7802658C>T 
T splice_region_ 
variant,intron_ 
variant 
CHD3 protein_ 
coding 
- 14/21 - - - 
HGVS name Allele Consequence Gene 
symbol 
Biotype Exon Intron HGVSp Amino 
acids 
Codons 
NC_000017.10: 
g.73897977C>T 
T upstream_gene_ 
variant 
TRIM65 protein_ 
coding 
- - - - - 
NC_000017.10: 
g.73897977C>T 
T missense_variant MRPL38 protein_ 
coding 
4/9 - - R/Q cGg/cAg 
NC_000017.10: 
g.73897977C>T 
T upstream_gene_ 
variant 
TRIM65 protein_ 
coding 
- - - - - 
NC_000017.10: 
g.73897977C>T 
T non_coding_ 
transcript_ 
exon_variant 
MRPL38 misc_RNA 4/8 - - - - 
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Supplementary statistical methods 
Let assume that we measured q phenotypic traits for n individuals with p recorded genotypic 
variants. The multivariate polygenic model for this data can be represented as    
𝒀nq×1 = 𝛍nq×1 + (𝑿n×p ⊗ 𝑰q)𝜷pq×1 + 𝑼nq×1 + 𝝐qn×1      (1) 
where 
𝝐 ~𝑁(𝟎, Σ), Σ𝑛𝑞×𝑛𝑞 = diag[Σ𝑖𝑖]𝑞×𝑞 ,  Σ𝑖𝑖 = diag[𝜎𝑖]𝑛×𝑛. 
Each entries of  𝒀 =  {𝑦𝑖𝑗}𝑖=1,…,𝑞
𝑗=1,…,𝑛
 represents ith trait recorded for jth individual, 𝛽𝑖𝑘 is the effect 
of kth genomic variants on ith trait in coefficient vector 𝜷 = {𝛽𝑖𝑘} 𝑖=1,…,𝑞
𝑘=1,…,𝑝
, vector 𝑼 =
{𝑢𝑖𝑗}𝑖=1,…,𝑞
𝑗=1,…,𝑛
 includes random effects corresponding to vector Y as   
𝑼 ~ 𝑁(𝟎, Ψ) 
where  
Ψ =  [
Ψ11 ⋯ Ψ1𝑞
⋮ ⋱ ⋮
Ψ𝑞1 ⋯ Ψ𝑞𝑞
],   
and Ψ𝑖𝑙 = {𝜓𝑗𝑔}𝑗=1,…𝑛,
𝑔=1,…,𝑛
,      𝑖, 𝑙 ∈ {1, … , 𝑞}. 
Without loss of generality, we assume 𝑦𝑖𝑗s are standardized and write the likelihood function as 
ℓ(𝜷, 𝑼, Σ, Ψ |𝒀) ∝ exp {−
1
2
 𝒆𝑇Σ−1𝒆} 
where 𝒆 = 𝒀 − (𝑿 ⊗ 𝑰𝑞)𝜷 − 𝑼. 
Bayesian network over traits: The large sample size (n) and large number of traits (q) introduce 
a large number of parameters into the model through Ψ and make the numerical algorithm of 
model (1) unstable and slow to converge. Therefore, to reduce the number of parameters in 
polygenic mixed model and provide larger precision for parameter estimations, we propose to 
estimate the sparse structure of precision matrix  Ψ−1 in priori using phenotypic data (individuals 
without genotype record) which is accessible in majority of medical studies. Here in particular, 
we apply a Bayesian network that relies on probabilistic graphical models to estimate sparse 
relationship among traits.  
Bayesian networks represent underlying relationship among traits based on efficient and 
effective representation of their joint probability distribution (1)(2)(3) where nodes represent 
traits and links represent partial correlations. A missing edge between two traits reveals that the 
two corresponding traits do not have a significant relationship after excluding effect of the other 
traits in the analysis. To learn about sparsity of precision matrix  Ψ−1 , we incorporate 
independencies inferred from Bayesian networks to reduce the number of parameters in the 
model and efficiently compute posterior probabilities. In the matrix  Ψ−1, we replace zero with 
the parameters corresponding to missing arrows in the identified Bayesian network over the 
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traits. To avoid overfitting, we identify the Bayesian network using the data on the set of 
individuals without genotype record. 
Prior Specification: There have been many studies on setting a prior distribution on precision 
matrix Ψ−1. The most common approach is to set Wishart distribution as prior on  Ψ−1 while it 
is conjugate prior for multivariate normal model. Wishart distribution is fully parameterized with 
a single degree of freedom parameter and scale matrix parameter. The degree of freedom 
parameter that needs to be larger than dimension of underling covariance matrix represents the 
strength of information surrounded around scale matrix parameter. Therefore, in large scale 
problems, this choice of prior yields to highly concentrated distribution about the scale 
matrix(4)(5)(6).  
The assumption of independent individuals that is held in many genetic studies leads to a sparse 
covariance matrix Ψ as  
Ψ =  [
Ψ11 ⋯ Ψ1𝑞
⋮ ⋱ ⋮
Ψ𝑞1 ⋯ Ψ𝑞𝑞
] , Ψ𝑖𝑙 = diag[𝜓𝑗𝑔],   𝑖, 𝑙 ∈ {1, … , 𝑛},    𝑗, 𝑔 ∈ {1, … , 𝑞}. 
To set prior on this matrix, we first rearrange vector U in order to be partition with individual's 
index j.  If we denote the rearranged random effect vector with 𝑼∗ such that 𝑼∗~ N(𝟎, Ψ∗), Ψ∗ is 
a block diagonal as 
Ψ∗ = [
Ψ11
∗ ⋯ 0
⋮ ⋱ ⋮
0 ⋯ Ψ𝑛𝑛
∗
] 
where each Ψ𝑗𝑗
∗  is a 𝑞 × 𝑞 dense matrix.  Ψ𝑗𝑗
∗  takes into account correlation among different traits 
for jth individual. While Ψ∗−1 is a block diagonal matrix and q is a small number, the use of 
Wishart prior for Ψ𝑗𝑗 
∗−1 is appropriate. Furthermore, we incorporate the identified relationship 
among the traits using Bayesian network and estimate the sparsity of  Ψ𝑗𝑗
∗−1and set G-Wishart 
(GW) distribution (7) as prior on Ψ𝑗𝑗
∗−1. G-Whishart distribution, which is a restricted domain of 
Wishart given constraints of network structure, provides sparse block diagonal matrix and 
reduces computational burden time. The density of G-Wishart is  
𝑝(Ψ𝑗𝑗
∗−1|BNT) = (𝐼𝐺𝑇(𝜈, Λ))
−1
|Ψ∗−1𝑗𝑗|
𝜈−2
2  exp {−
1
2
tr(ΛΨ∗−1𝑗𝑗)} 
where BNT stands for the Bayesian Networks over the traits, and   
𝐼𝐺𝑇(𝜈, Λ) = ∫ |Ψ𝑗𝑗
∗−1|(𝜈−2)/2 exp {−
1
2
tr(ΛΨ𝑗𝑗
∗−1)}  dΨ𝑗𝑗
∗−1 
is the normalizing constant, which is finite for 𝜈 > 2 .This results in a reduction of the number of 
parameters in polygenic mixed model, and consequently expedites the convergence of the 
algorithm.  
We set conjugate prior for other hyperparameters of the model as 
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𝜷~N (0, 𝛀) 
where  
Ω𝑝𝑞×𝑝𝑞 = diag [Ω𝑘𝑘]𝑝×𝑝, Ω𝑘𝑘 = diag [𝜎𝑗]𝑝×𝑝 
and 
𝜎𝑖~ 𝐼𝐺 (
𝑎1
2
,
𝑏1
2
) 
The aforementioned prior specification leads to Gibbs sampling scheme for the model with the 
graphical representation shown in the following Figure.  
 
 
 
 
 
 
 
 
 
 
 
 
 Graphical representation of the model 
 
 
 
 
 
Gibbs Sampling Scheme of IBMT: 
𝜷𝑖 ∣ 𝒚𝑖, 𝒖𝑖, 𝝈𝑖  ∼ N [ (𝑿
𝑇𝑿 +  𝑰)−1𝑿−1(𝒚𝑖 − 𝒖𝑖), 𝜎𝑖(𝑿
𝑇𝑿 + 𝑰)−1] 
𝐮j
∗ ∣ 𝐮j, 𝚿jj
∗, 𝚺jj ∼ N [ (𝚿jj
∗ +   𝚺jj
−1)
−1
 𝚺𝑗𝑗
−1𝐳𝑗, (Ψjj
∗ + Σ𝑗𝑗
−1)
−1
] 
 𝜎𝑖 ∣ 𝒚𝑖, 𝜷𝑖, 𝒖𝑖 ∼  ING [ 
𝑛+𝑝+𝑎1
2
,
1
2
(𝒆𝑖 
𝑇𝒆𝑖 + 𝜷𝑖
𝑇𝜷𝑖 + 𝑏1)] 
𝚿𝑗𝑗
∗−1 ∣ 𝒖𝑗 ∼ 𝐺W[ 𝚲 +    𝒖𝑗
𝑇𝒖𝑗, 𝜈 + 𝑞] 
 
where 𝒆𝒊 =   (𝒀𝒊 −  𝑿𝜷𝒊 − 𝑼𝒊) and vector Z is obtained after reordering entries of vector (𝒀 −
 𝑿 ⊗  𝑰𝑞) 𝜷  in order to be  partitioned by each individual similar to 𝑼
∗. 
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